V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20210844 | 20088600 | 1.63 | 82.6 | null | 2019-04-27 | 2019-05-04 | Doxorubicin + Olaratumab | 01 | N | BORTEZOMIB + MELPHALAN | 100494692 |
| 20210893 | 20088601 | 1.65 | 86.6 | Palliative (P) | 2018-08-19 | 2018-08-25 | CTD | 02 | N | VENETOCLAX | 101295603 |
| 20210918 | 20088602 | 1.6 | 52.6 | Neo-adjuvant (N) | 2016-07-26 | 2016-07-26 | Capital Trial | 02 | N | CAPECITABINE + OXALIPLATIN + RT | 100555649 |
| 20210925 | 20088603 | null | 78.8 | 03 | 2018-06-11 | 2018-06-24 | Irinotecan | N | N | MCX | 101137047 |
| 20210930 | 20088604 | 1.78 | 140 | 03 | 2019-06-20 | 2019-07-06 | GO2 TRIAL | 02 | N | ACTICCA-1 TRIAL | 101413441 |
| 20210988 | 20088605 | 1.72 | 49.1 | 03 | 2018-02-13 | 2018-02-22 | OXALIPLATIN | 01 | N | EVEROLIMUS | 101618503 |
| 20210999 | 20088606 | 1.81 | 71.5 | Palliative (P) | 2019-02-24 | 2019-02-26 | PLATO Trials | N | N | PLATO TRIAL | 100573211 |
| 20211066 | 20088607 | 1.79 | 78.1 | Palliative (P) | 2019-04-29 | 2019-04-29 | EOF | 02 | N | CAPECITABINE + OXALIPLATIN + RT | 100559799 |
| 20211086 | 20088608 | 1.69 | 100 | 03 | 2016-12-30 | 2017-01-22 | IRINOTECAN + MDG + PANITUMUMAB | 01 | N | CISPLATIN + RT | 100640647 |
| 20211131 | 20088609 | 0 | 11.5 | Palliative (P) | 2020-06-13 | 2020-06-13 | Capecitabine + Docetaxel | 02 | N | CARBOPLATIN + EPIRUBICIN + FLUOROURACIL | 100965481 |
| 20211169 | 20088611 | 0 | 7.1 | Palliative (P) | 2017-10-29 | 2017-11-08 | Capecitabine + Carboplatin + RT | 02 | Y | BLEOMYCIN + CISPLATIN + ETOPOSIDE | 101578880 |
| 20211198 | 20088612 | 1.52 | 76 | Palliative (P) | 2019-01-24 | 2019-01-31 | CISPLATIN + FLUOROURACIL + RT | 02 | N | BENDAMUSTINE + RITUXIMAB | 100199856 |
| 20211333 | 20088614 | 0 | 12.9 | Palliative (P) | 2018-06-11 | 2018-07-01 | EEF or EOF | 02 | N | RALTITREXED | 101221870 |
| 20211468 | 20088615 | 1.44 | 81.1 | Palliative (P) | 2018-10-28 | 2018-10-28 | ACTICCA-1 Trial | 02 | N | BEVACIZUMAB + IRINOTECAN + MDG | 101308700 |
| 20211503 | 20088616 | 1.69 | 55.2 | null | 2019-11-29 | 2019-12-22 | ECarboX | 02 | N | POMALIDOMIDE | 101615999 |
| 20211540 | 20088617 | 1.63 | 126 | Palliative (P) | 2020-12-05 | 2020-12-05 | Doxorubin 50mg/m2 | 02 | N | BALLAD TRIAL | 100241098 |
| 20211543 | 20088618 | 1.6 | 62.8 | Palliative (P) | 2017-10-22 | 2017-11-06 | NEO-AEGIS TRIAL | 02 | null | RALTITREXED | 100901858 |
| 20211578 | 20088619 | 1.75 | 61.4 | 03 | 2016-12-20 | 2017-01-11 | Temozolomide + RT | 02 | N | TCX | 100774675 |
| 20211673 | 20088620 | 2.01 | 57 | 03 | 2018-07-01 | 2018-07-06 | Carbo F | 02 | N | OXALIPLATIN + MDG + PANITUMUMAB | 100408345 |
| 20211713 | 20088621 | 1.59 | null | Palliative (P) | 2017-01-11 | 2017-01-20 | null | 02 | N | CARBOPLATIN + FLUOROURACIL + STREPTOZOCIN | 100325217 |
| 20211729 | 20088622 | 1.68 | 55 | Palliative (P) | 2017-12-15 | 2017-12-15 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | null | DOCETAXEL | 100070495 |
| 20211797 | 20088623 | 1.67 | 72.4 | Palliative (P) | 2018-01-07 | 2018-01-25 | CAPECITABINE + CARBOPLATIN + Trastuzumab | 01 | N | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100823182 |
| 20211832 | 20088624 | 1.5 | 70 | Palliative (P) | null | 2019-07-25 | Capecitabine + Streptozocin | 2 | N | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 100669608 |
| 20211883 | 20088625 | 1.72 | 66.8 | null | 2017-05-08 | 2017-05-08 | OXALIPLATIN | 02 | N | ACELARATE TRIAL | 101557994 |
| 20211922 | 20088626 | 1.58 | 55.2 | Adjuvant (A) | 2021-01-17 | 2021-01-24 | COSMIC TRIAL | 02 | N | BENDAMUSTINE + RITUXIMAB | 101222868 |
| 20211925 | 20088627 | 1.53 | 40.4 | 03 | null | 2021-08-30 | CAPECITABINE + OXALIPLATIN + RT | 02 | N | DOCETAXEL | 100754310 |
| 20211930 | 20088628 | 0 | 0 | Adjuvant (A) | 2018-04-26 | 2018-05-03 | CAP + RT | 02 | N | RITUXIMAB | 100449568 |
| 20211941 | 20088629 | 1.82 | 76 | 03 | 2017-03-04 | 2017-03-25 | DOXORUBICIN | 02 | N | CARBOPLATIN + FLUOROURACIL | 101825570 |
| 20212055 | 20088631 | 1.6 | 104 | Palliative (P) | 2018-11-14 | 2018-11-22 | HEP HR Hepatoblastoma guide cisp | N | N | CVD | 100567125 |
| 20212058 | 20088632 | 0 | 0 | Palliative (P) | 2017-09-22 | 2017-09-23 | Cisplatin + Fluorouracil + Streptozocin | 02 | N | PACLITAXEL | 101481757 |
| 20212094 | 20088633 | 1.8 | 89.2 | Palliative (P) | 2019-08-13 | 2019-08-21 | CAPECITABINE + CARBOPLATIN + Trastuzumab | 01 | N | SCOPE2 TRIAL | 100203168 |
| 20212109 | 20088634 | null | 63.4 | 03 | 2017-12-29 | 2017-12-30 | ARISTOTLE TRIAL | 02 | Y | PHITT | 101414463 |
| 20212138 | 20088635 | 1.75 | 83.4 | 03 | 2017-11-29 | 2017-11-29 | IRINOTECAN + MDG + PANITUMUMAB | null | N | ACELARATE TRIAL | 100461963 |
| 20212159 | 20088636 | 1.72 | 89.9 | Palliative (P) | 2016-06-02 | 2016-06-05 | WT Guidelines Cyclophos/Doxorubicin | 01 | N | RALTITREXED | 100016305 |
| 20212242 | 20088637 | 1.75 | 87 | 03 | 2018-12-11 | 2018-12-14 | null | Y | N | BUSULFAN | 101149235 |
| 20212261 | 20088638 | 1.52 | 62.2 | Palliative (P) | 2021-07-02 | 2021-07-16 | ACELARATE Trial | 01 | N | EVEROLIMUS | 100465631 |
| 20212282 | 20088639 | 1.66 | 50.4 | Palliative (P) | 2019-10-02 | 2019-10-02 | PRIMUS 002 TRIAL | 02 | N | POMALIDOMIDE | 101382333 |
| 20212294 | 20088640 | null | 64.5 | 03 | 2019-10-28 | 2019-10-29 | PLATO Trials | 02 | N | PLATO TRIAL | 100988487 |
| 20212309 | 20088641 | 0.89 | 55.2 | 03 | 2017-05-08 | 2017-05-08 | LENALIDOMIDE | 02 | N | DOXORUBICIN | 100902814 |
| 20212405 | 20088643 | 0 | 0 | null | 2016-05-09 | 2016-05-31 | FCarboSt | 02 | N | PANITUMUMAB | 101695783 |
| 20212420 | 20088644 | null | 63.5 | 03 | 2017-02-26 | 2017-02-26 | ESPAC-4 TRIAL | 01 | N | EVEROLIMUS | 100936002 |
| 20212476 | 20088645 | 1.82 | 59 | Adjuvant (A) | null | 2019-02-28 | CHOP R | 01 | N | PANITUMUMAB | 100026937 |
| 20212512 | 20088646 | 1.6 | 52.2 | Neo-adjuvant (N) | 2020-01-09 | 2020-01-20 | PACLITAXEL | N | null | EVEROLIMUS | 101638396 |
| 20212591 | 20088647 | 0 | 8.5 | 03 | 2017-08-24 | 2017-09-13 | null | N | N | CHOP R | 101849529 |
| 20212653 | 20088648 | 1.79 | 68 | Adjuvant (A) | 2017-09-03 | 2017-09-05 | SCOPE 2 TRIAL | 01 | N | OXALIPLATIN + MDG + PANITUMUMAB | 101317133 |
| 20212887 | 20088650 | 1.01 | 64 | Adjuvant (A) | 2017-01-15 | 2017-01-18 | MCX | 02 | N | BCG | 101719179 |
| 20212931 | 20088651 | null | 93.9 | Palliative (P) | 2020-03-11 | 2020-03-26 | ARISTOTLE TRIAL | null | N | CISPLATIN + TEYSUNO | 101398419 |
| 20213063 | 20088653 | 1.61 | 85.5 | 03 | 2018-01-11 | 2018-01-12 | CAPECITABINE + CETUXIMAB + IRINOTECAN | 02 | N | SUNITINIB | 100186456 |
| 20213085 | 20088654 | 1.63 | 67.9 | Palliative (P) | 2019-09-20 | 2019-09-20 | MITOMYCIN | 02 | N | LIPOSOMAL DOXORUBICIN | 101296337 |
| 20213113 | 20088656 | 1.68 | 64.2 | Palliative (P) | 2022-03-22 | 2022-04-06 | Raltitrexed | 02 | N | OXALIPLATIN | 101740336 |